Stock Scorecard
Stock Summary for NovoCure Ltd (NVCR) - $14.53 as of 3/28/2024 8:08:50 AM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NVCR
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NVCR
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NVCR
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for NVCR
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for NVCR
Financial Details for NVCR
Company Overview |
|
---|---|
Ticker | NVCR |
Company Name | NovoCure Ltd |
Country | USA |
Description | NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey. |
Sector Name | LIFE SCIENCES |
Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 14.53 |
Last Day Price Updated | 3/28/2024 8:08:50 AM EST |
Last Day Volume | 11,920,571 |
Average Daily Volume | 1,055,234 |
52-Week High | 83.60 |
52-Week Low | 10.87 |
Last Price to 52 Week Low | 33.67% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 50.34 |
Sector PE | 60.76 |
5-Year Average PE | -225.69 |
Free Cash Flow Ratio | 1.71 |
Industry Free Cash Flow Ratio | 67.97 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 5.78 |
Total Cash Per Share | 8.50 |
Book Value Per Share Most Recent Quarter | 3.38 |
Price to Book Ratio | 3.90 |
Industry Price to Book Ratio | 5.28 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 2.75 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.37 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 107,093,000 |
Market Capitalization | 1,556,061,290 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -6.00% |
Annual Earnings Growth | -123.75% |
Reported EPS 12 Trailing Months | -1.95 |
Reported EPS Past Year | -1.95 |
Reported EPS Prior Year | -0.88 |
Net Income Twelve Trailing Months | -207,043,000 |
Net Income Past Year | -207,043,000 |
Net Income Prior Year | -92,534,000 |
Quarterly Revenue Growth YOY | 4.20% |
5-Year Revenue Growth | 15.47% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 910,616,000 |
Total Cash Past Year | 910,616,000 |
Total Cash Prior Year | 969,425,000 |
Net Cash Position Most Recent Quarter | 341,794,000 |
Net Cash Position Past Year | 341,794,000 |
Long Term Debt Past Year | 568,822,000 |
Long Term Debt Prior Year | 565,509,000 |
Total Debt Most Recent Quarter | 568,822,000 |
Equity to Debt Ratio Past Year | 0.39 |
Equity to Debt Ratio Most Recent Quarter | 0.39 |
Total Stockholder Equity Past Year | 362,496,000 |
Total Stockholder Equity Prior Year | 441,170,000 |
Total Stockholder Equity Most Recent Quarter | 362,496,000 |
Options |
|
Put/Call Ratio | 0.43 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.34 |
MACD Signal | 0.02 |
20-Day Bollinger Lower Band | 11.15 |
20-Day Bollinger Middle Band | 13.96 |
20-Day Bollinger Upper Band | 16.77 |
Beta | 0.41 |
RSI | 39.62 |
50-Day SMA | 29.83 |
200-Day SMA | 87.91 |
System |
|
Modified | 3/27/2024 2:53:03 AM EST |